0
Tu carrito

Profesionales

Profesionales

Distribución

Si estás interesado en distribuir cualquiera de nuestros productos, o necesitas más información al respecto, puedes contactarnos en:

info@ebiotec.com

AnimónComplex

Antianémico. Prometabólico (disminuye la fatiga y el cansancio). Neuroprotector. Refuerza la función psicológica, en casos de depresión, ansiedad, estrés o apatía.

Ficha técnica
Data Sheet
  1. Peters R, Burch L, Warner J, Beckett N, Poulter R, Bulpitt C. 2008. Haemoglobin, anaemia, dementia and cognitive decline in the elderly, a systematic review. BMC Geriatr, 8, 8:18.
    https://bmcgeriatr.biomedcentral.com/articles/10.1186/1471-2318-8-18
  2. Abugoch James LE. 2009. Quinoa (Chenopodium quinoa Willd.): composition, chemistry, nutritional, and functional properties. Adv Food Nutr Res, 58:1-31.
    https://www.sciencedirect.com/science/article/pii/S1043452609580011?via%3Dihub
  3. Shipton MJ, Thachil J. 2015. Vitamin B12 deficiency – A 21st century perspective. Clin Med, 15(2):145-50.
    https://www.rcpjournals.org/content/clinmedicine/15/2/145
  4. Bailey LB, Stover PJ, McNulty H, Fenech MF, Gregory JF 3rd, Mills JL, et al. 2015. Biomarkers of Nutrition for Development-Folate Review. J Nutr, 145(7):1636S-80S.
    https://academic.oup.com/jn/article/145/7/1636S/4589945

AntiGan

Indicado para mejorar la tolerancia a los tratamientos oncológicos convencionales.

Ficha técnica
Data Sheet
  1. Lombardi VRM, Pereira J, Etcheverría I, Fernández-Novoa L, Seoane S and Cacabelos R. 2006. Improvement of immune function by means of Conger conger extract in an in vivo rat model of cold stress. Food and Agricultural Immunology, 17(1-4): 115-127.
    https://www.tandfonline.com/doi/full/10.1080/09540100600916569
  2. Cacabelos R. 2016. Novel Biotechnological Products from Natural Sources: Nutri/Pharmacogenomic Component. J Nutr Food Sci, 6:6.
    https://www.longdom.org/open-access/novel-biotechnological-products-from-natural-sources-nutri-pharmacogenomic-component-2155-9600-1000e135.pdf
  3. Cacabelos R. 2017. ProteoLipins and LipoFishins: Novel nutraceuticals and their effects. Open Access Government. Health & Social Care News, January 20.
    https://www.openaccessgovernment.org/proteolipins-lipofishins-novel-nutraceuticals-effects/31137/
  4. Lombardi VRM, Carrera I, Cacabelos R. 2018. In vitro and in vivo cytotoxic effect of AntiGan against tumor cells. Exp Ther Med, 15(3):2547-2556.
    https://www.spandidos-publications.com/10.3892/etm.2017.5681
  5. Cacabelos R, Lombardi VRM, Fernández-Novoa l, Carrera I, Cacabelos P, Corzo L, Carril JC, Teijido O. 2018. Chapter 6 – Basic and Clinical Studies with Marine LipoFishins and Vegetal Favalins in Neurodegeneration and Age-Related Disorders. Volume 59, Pages 195-225.
    https://www.sciencedirect.com/science/article/pii/B9780444641793000062
  6. Lombardi VRM, Carrera I, Corzo L, Cacabelos R. 2019. Role of bioactive lipofishins in prevention of inflammation and colon cancer. Seminars in Cancer Biology, Vol 56, Pages 175-184.
    https://www.sciencedirect.com/science/article/abs/pii/S1044579X17302559
  7. Corzo L, Fernández-Novoa L, Carrera I, Martínez O, Rodríguez S, Alejo R and Cacabelos R. Nutrition, Health, and Disease: Role of Selected Marine and Vegetal Nutraceuticals. Nutrients 2020, 12(3):747.
    https://www.mdpi.com/2072-6643/12/3/747
  8. Martínez-Iglesias O, Carrera I, Naidoo V, Cacabelos R. 2022. AntiGan: An Epinutraceutical Bioproduct with Antitumor Properties in Cultured Cell Lines. Life, 12 (1), 97.
    https://doi.org/10.3390/life12010097
  9. Watanabe Y, Naganuma T, Ogawa T, Muramoto K. 2013. Lectins of Marine Origin and Their Clinical Applications. In: Fang E., Ng T. (eds) Antitumor Potential and other Emerging Medicinal Properties of Natural Compounds. Springer, Dordrecht.
    https://doi.org/10.1007/978-94-007-6214-5_4
  10. Nakamura O, Watanabe T, Kamiya H, Muramoto K. 2001. Galectin containing cells in the skin and mucosal tissues in Japanese conger eel, Conger myriaster: an immunohistochemical study. Developmental and Comparative Immunology. 25(5-6):431-437.
    https://doi.org/10.1016/S0145-305X(01)00012-X
  11. Kwak CH, Lee SH, Lee SK, Ha SH, Suh SJ, Kwon KM, et al. 2015. Induction of Apoptosis and Antitumor Activity of Eel Skin Mucus, Containing Lactose-Binding Molecules, on Human Leukemic K562 Cells. Mar. Drugs, 13, 3936-3949.
    https://doi.org/10.3390/md13063936

AtreMorine

Fuente natural de L-Dopa. Tratamiento y/o prevención de enfermedades neurodegenerativas, enfermedad de Parkinson y otros síndromes parkinsonianos. Antioxidante.

Ficha técnica
Data Sheet
  1. Cacabelos R, Fernández-Novoa L, Alejo R, Corzo L, Alcaraz M, Nebril L, et al. 2016. E-PodoFavalin-15999 (Atremorine®)-Induced Dopamine Response in Parkinson’s disease: Pharmacogenetics-Related Effects. Gen Med Pharm, 1(1):1‐26.

    https://www.scitcentral.com/article/20/75/E-PodoFavalin-15999-(Atremorine%C2%AE)-Induced-Dopamine-Response-in-Parkinson%E2%80%99s-Disease:-Pharmacogenetics-Related-Effects

  2. Cacabelos R, Fernández-Novoa L, Alejo R, Corzo L, Alcaraz M, Nebril L, et al. 2016. E-PodoFavalin-15999 (Atremorine®) -Induced Neurotransmitter and Hormonal Response in Parkinson’s Disease. J Exp Res Pharm, 1(1):1-12.

    http://www.xiahepublishing.com/ArticleFullText.aspx?sid=2&jid=3&id=10.14218%2FJERP.2016.00031

  3. Cacabelos R. 2016. Novel Biotechnological Products from Natural Sources: Nutri/Pharmacogenomic Component. J Nutr Food Sci, 6:6.

    https://www.longdom.org/open-access/novel-biotechnological-products-from-natural-sources-nutri-pharmacogenomic-component-2155-9600-1000e135.pdf

  4. Cacabelos R, Carril JC, Teijido O. 2017. Chapter 5. Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development. Anti-aging Drugs: From Basic Research to Clinical Practice, 75-141.

    https://pubs.rsc.org/en/content/chapter/bk9781782624356-00075/978-1-78262-435-6

  5. Romero A, Parada E, González‐Lafuente L, Farré‐Alins V, Ramos E, Cacabelos R, Egea J. 2017. Neuroprotective effects of E‐PodoFavalin‐15999 (Atremorine®). CNS Neurosci Ther, 23:450‐452.

  6. https://onlinelibrary.wiley.com/doi/full/10.1111/cns.12693

  7. Cacabelos R. 2017. Parkinson’s Disease: From Pathogenesis to Pharmacogenomics. Int. J. Mol. Sci. 18(3), 551.
    https://www.mdpi.com/1422-0067/18/3/551

  8. Carrera I, Fernandez-Novoa L, Sampedro C, Cacabelos R. 2017. Neuroprotective Effect of AtreMorine in an Experimental Model of Parkinson’s disease. Current Pharmaceutical Design, Vol 23 (18): 2673-2684(12).
    https://www.ingentaconnect.com/contentone/ben/cpd/2017/00000023/00000018/art00011#expand/collapse
  9. Cacabelos R, Carril JC, Cacabelos P, Fernández-Novoa L, Arun M. 2017. Pharmacogenetics of Neurodegenerative disorders. Internal Medicine Review, 3. 10.18103/imr.v3i6.472.
    https://internalmedicinereview.org/index.php/imr/article/view/472
  10. Cacabelos R, Lombardi VRM, Fernández-Novoa l, Carrera I, Cacabelos P, Corzo L, et al. 2018. Chapter 6 – Basic and Clinical Studies with Marine LipoFishins and Vegetal Favalins in Neurodegeneration and Age-Related Disorders. Volume 59, Pages 195-225.
    https://www.sciencedirect.com/science/article/pii/B9780444641793000062

     

  11. Teijido O., Cacabelos R. 2018. Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer’s and Parkinson’s Diseases. Int. J. Mol. Sci. 19, 3199.

    https://www.mdpi.com/1422-0067/19/10/3199

  12. Cacabelos R, Carrera I, Alejo R, Fernández-Novoa L, Cacabelos P, Corzo L, et al. 2019. Pharmacogenetics of Atremorine-Induced Neuroprotection and Dopamine Response in Parkinson’s Disease. Planta Med, 85(17):1351-1362.
    https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1013-7686

     

  13. Carrera I, Cacabelos R. 2019. Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease. Current Neuropharmacol, Volume 17, 3, pp. 295-306(12).
    https://doi.org/10.2174/1570159X17666181127125704

     

  14. Carrera I, Martinez O, Cacabelos R. 2019. Neuroprotection with Natural Antioxidants and Nutraceuticals in the Context of Brain Cell Degeneration: The Epigenetic Connection. Curr Top Med Chem, 19(32):2999-3011.
    10.2174/1568026619666191202155738

     

  15. Cacabelos R. 2020. Pharmacogenomics of Alzheimer’s and Parkinson’s diseases. Neurosci Lett, 726: 133807.
    https://doi.org/10.1016/j.neulet.2018.09.018

     

  16. Corzo L, Fernández-Novoa L, Carrera I, Martínez O, Rodríguez S, Alejo R and Cacabelos R. 2020. Nutrition, Health, and Disease: Role of Selected Marine and Vegetal Nutraceuticals. Nutrients, 12(3):747.
    https://www.mdpi.com/2072-6643/12/3/747

     

  17. Martínez-Iglesias O, Naidoo V, Carril JC, Carrera I, Corzo L, Rodríguez S, et al. 2020. AtreMorine Treatment Regulates DNA Methylation in Neurodegenerative Disorders: Epigenetic and Pharmacogenetic Studies. Current Pharmacogenomics and Personalized Medicine, 17, 159-171.
    http://dx.doi.org/10.2174/1875692117999201231152800

     

  18. Cacabelos R, Carrera I, Martínez O, Naidoo V, Cacabelos N, Aliev G, Carril JC. 2021. Influence of dopamine, noradrenaline, and serotonin transporters on the pharmacogenetics of Atremorine in Parkinson’s disease. Drug Dev Res, 1–12.
    https://doi.org/10.1002/ddr.21784

     

  19. Cacabelos R, Carrera I, Martínez O, Alejo R, Fernandez-Novoa L, Cacabelos P, et al. 2021. Atremorine in Parkinson’s disease: From dopaminergic neuroprotection to pharmacogenomics. Med Res Rev, 1–46.
    https://doi.org/10.1002/med.21838

AtreMorine 100 Cápsulas

Contiene L-dopa natural. Antioxidante.

Ficha técnica
  1. Cacabelos R, Fernández-Novoa L, Alejo R, Corzo L, Alcaraz M, Nebril L, et al. 2016. E-PodoFavalin-15999 (Atremorine®)-Induced Dopamine Response in Parkinson’s disease: Pharmacogenetics-Related Effects. Gen Med Pharm, 1(1):1‐26.
    https://www.scitcentral.com/article/20/75/E-PodoFavalin-15999-(Atremorine%C2%AE)-Induced-Dopamine-Response-in-Parkinson%E2%80%99s-Disease:-Pharmacogenetics-Related-Effects
  2. Cacabelos R, Fernández-Novoa L, Alejo R, Corzo L, Alcaraz M, Nebril L, et al. 2016. E-PodoFavalin-15999 (Atremorine®) -Induced Neurotransmitter and Hormonal Response in Parkinson’s Disease. J Exp Res Pharm, 1(1):1-12.
    http://www.xiahepublishing.com/ArticleFullText.aspx?sid=2&jid=3&id=10.14218%2FJERP.2016.00031
  3. Cacabelos R. 2016. Novel Biotechnological Products from Natural Sources: Nutri/Pharmacogenomic Component. J Nutr Food Sci, 6:6.
    https://www.longdom.org/open-access/novel-biotechnological-products-from-natural-sources-nutri-pharmacogenomic-component-2155-9600-1000e135.pdf
  4. Cacabelos R, Carril JC, Teijido O. 2017. Chapter 5. Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development. Anti-aging Drugs: From Basic Research to Clinical Practice, 75-141.
    https://pubs.rsc.org/en/content/chapter/bk9781782624356-00075/978-1-78262-435-6
  5. Romero A, Parada E, González‐Lafuente L, Farré‐Alins V, Ramos E, Cacabelos R, Egea J. 2017. Neuroprotective effects of E‐PodoFavalin‐15999 (Atremorine®). CNS Neurosci Ther, 23:450‐452.
    https://onlinelibrary.wiley.com/doi/full/10.1111/cns.12693
  6. Cacabelos R. 2017. Parkinson’s Disease: From Pathogenesis to Pharmacogenomics. Int. J. Mol. Sci. 18(3), 551.
    https://www.mdpi.com/1422-0067/18/3/551
  7. Carrera I, Fernandez-Novoa L, Sampedro C, Cacabelos R. 2017. Neuroprotective Effect of AtreMorine in an Experimental Model of Parkinson’s disease. Current Pharmaceutical Design, Vol 23 (18): 2673-2684(12).
    https://www.ingentaconnect.com/contentone/ben/cpd/2017/00000023/00000018/art00011#expand/collapse
  8. Cacabelos R, Carril JC, Cacabelos P, Fernández-Novoa L, Arun M. 2017. Pharmacogenetics of Neurodegenerative disorders. Internal Medicine Review, 3. 10.18103/imr.v3i6.472.
    https://internalmedicinereview.org/index.php/imr/article/view/472
  9. Cacabelos R, Lombardi VRM, Fernández-Novoa l, Carrera I, Cacabelos P, Corzo L, et al. 2018. Chapter 6 – Basic and Clinical Studies with Marine LipoFishins and Vegetal Favalins in Neurodegeneration and Age-Related Disorders. Volume 59, Pages 195-225.
    https://www.sciencedirect.com/science/article/pii/B9780444641793000062
  10. Teijido O., Cacabelos R. 2018. Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer’s and Parkinson’s Diseases. Int. J. Mol. Sci. 19, 3199.
    https://www.mdpi.com/1422-0067/19/10/3199
  11. Cacabelos R, Carrera I, Alejo R, Fernández-Novoa L, Cacabelos P, Corzo L, et al. 2019. Pharmacogenetics of Atremorine-Induced Neuroprotection and Dopamine Response in Parkinson’s Disease. Planta Med, 85(17):1351-1362.
    https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1013-7686
  12. Carrera I, Cacabelos R. 2019. Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease. Current Neuropharmacol, Volume 17, 3, pp. 295-306(12).
    https://doi.org/10.2174/1570159X17666181127125704
  13. Carrera I, Martinez O, Cacabelos R. 2019. Neuroprotection with Natural Antioxidants and Nutraceuticals in the Context of Brain Cell Degeneration: The Epigenetic Connection. Curr Top Med Chem, 19(32):2999-3011.
    10.2174/1568026619666191202155738
  14. Cacabelos R. 2020. Pharmacogenomics of Alzheimer’s and Parkinson’s diseases. Neurosci Lett, 726: 133807.
    https://doi.org/10.1016/j.neulet.2018.09.018
  15. Corzo L, Fernández-Novoa L, Carrera I, Martínez O, Rodríguez S, Alejo R and Cacabelos R. 2020. Nutrition, Health, and Disease: Role of Selected Marine and Vegetal Nutraceuticals. Nutrients, 12(3):747.
    https://www.mdpi.com/2072-6643/12/3/747
  16. Martínez-Iglesias O, Naidoo V, Carril JC, Carrera I, Corzo L, Rodríguez S, et al. 2020. AtreMorine Treatment Regulates DNA Methylation in Neurodegenerative Disorders: Epigenetic and Pharmacogenetic Studies. Current Pharmacogenomics and Personalized Medicine, 17, 159-171.
    http://dx.doi.org/10.2174/1875692117999201231152800
  17. Cacabelos R, Carrera I, Martínez O, Naidoo V, Cacabelos N, Aliev G, Carril JC. 2021. Influence of dopamine, noradrenaline, and serotonin transporters on the pharmacogenetics of Atremorine in Parkinson’s disease. Drug Dev Res, 1–12.
    https://doi.org/10.1002/ddr.21784
  18. Cacabelos R, Carrera I, Martínez O, Alejo R, Fernandez-Novoa L, Cacabelos P, et al. 2021. Atremorine in Parkinson’s disease: From dopaminergic neuroprotection to pharmacogenomics. Med Res Rev, 1–46.
    https://doi.org/10.1002/med.21838

CabyMar

Deporte y ejercicio. Mantenimiento y recuperación de la masa muscular, favorece el metabolismo energético y aumenta la eficiencia energética.

Ficha técnica
Data Sheet
  1. Lombardi VRM, Fernandez-Novoa L, Etcheverria I, Seoane S, Cacabelos R. 2005. Studies on immunological, biochemical, hematological and growth regulation by Scomber scombrus fish protein extract supplementation in young pigs. Animal Science Journal, 76: 159-170.
    https://onlinelibrary.wiley.com/doi/10.1111/j.1740-0929.2005.00252.x
  2. Cacabelos R. 2005. Role of Nutrition in the Prevention of Alzheimer´s Disease. Aging Health, 1(3): 359-362.
    https://www.futuremedicine.com/doi/abs/10.2217/1745509X.1.3.359
  3. Lombardi VRM, Fernandez-Novoa L, Etcheverria I, Seoane S, Cacabelos R. 2005. Effects of fish-derived lipoprotein extracts on activation markers, Fas expression and apoptosis in peripheral blood lymphocytes. International Immunopharmacology, 5: 253-262.
    https://www.sciencedirect.com/science/article/pii/S1567576904003157?via%3Dihub
  4. Cacabelos R. 2016. Novel Biotechnological Products from Natural Sources: Nutri/Pharmacogenomic Component. J Nutr Food Sci, 6:6.
    https://www.longdom.org/open-access/novel-biotechnological-products-from-natural-sources-nutri-pharmacogenomic-component-2155-9600-1000e135.pdf
  5. Cacabelos R. 2017. ProteoLipins and LipoFishins: Novel nutraceuticals and their effects. Open Access Government. Health & Social Care News, January 20.
  6. Cacabelos R, Lombardi VRM, Fernández-Novoa l, Carrera I, Cacabelos P, Corzo L, Carril JC, Teijido O. 2018. Chapter 6 – Basic and Clinical Studies with Marine LipoFishins and Vegetal Favalins in Neurodegeneration and Age-Related Disorders. Volume 59, Pages 195-225.
    https://www.sciencedirect.com/science/article/pii/B9780444641793000062
  7. Corzo L, Fernández-Novoa L, Carrera I, Martínez O, Rodríguez S, Alejo R, Cacabelos R. 2020. Nutrition, Health, and Disease: Role of Selected Marine and Vegetal Nutraceuticals. Nutrients 2020, 12(3):747.
    https://www.mdpi.com/2072-6643/12/3/747

DefenVid

Refuerza el sistema inmunitario en las épocas de catarros y resfriados (primavera y otoño). Antiinflamatorio. Antialérgico.

Ficha técnica
Data Sheet
  1. Lombardi VRM, Fernandez-Novoa L, Corzo D, Zas R, Cacabelos R. 2002. Enhancement in Immune Function and Growth Using E-JUR-94013®. Methods Find Exp Pharmacol, 24 (9): 573:578.
    https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=6&p_RefId=802309&p_IsPs=N
  2. Lombardi VRM, Fernandez-Novoa L, Etcheverria I, Seoane S, Cacabelos R. 2005. Effects of fish-derived lipoprotein extracts on activation markers, Fas expression and apoptosis in peripheral blood lymphocytes. International Immunopharmacology, 5: 253-262.
    https://www.sciencedirect.com/science/article/pii/S1567576904003157?via%3Dihub
  3. Cacabelos R. 2005. Role of Nutrition in the Prevention of Alzheimer´s Disease. Aging Health, 1(3): 359-362.
    https://www.futuremedicine.com/doi/abs/10.2217/1745509X.1.3.359
  4. Cacabelos R. 2016. Novel Biotechnological Products from Natural Sources: Nutri/Pharmacogenomic Component. J Nutr Food Sci, 6:6.
    https://www.longdom.org/open-access/novel-biotechnological-products-from-natural-sources-nutri-pharmacogenomic-component-2155-9600-1000e135.pdf
  5. Cacabelos R. 2017. ProteoLipins and LipoFishins: Novel nutraceuticals and their effects. Open Access Government. Health & Social Care News, January 20.
  6. Cacabelos R, Carril JC, Teijido O. 2017. Chapter 5. Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development. Anti-aging Drugs: From Basic Research to Clinical Practice, 75-141.
    https://pubs.rsc.org/en/content/chapter/bk9781782624356-00075/978-1-78262-435-6
  7. Lombardi VRM, Corzo L, Carrera I and Cacabelos R. 2018. The search for biomarine derived compounds with immunomodulatory activity. J Explor Res Pharmacol, 3(1):30.
    http://www.xiahepublishing.com/2572-5505/ArticleFullText.aspx?sid=2&id=10.14218%2FJERP.2018.00006
  8. Cacabelos R, Lombardi VRM, Fernández-Novoa l, Carrera I, Cacabelos P, Corzo L, Carril JC, Teijido O. 2018. Chapter 6 – Basic and Clinical Studies with Marine LipoFishins and Vegetal Favalins in Neurodegeneration and Age-Related Disorders. Volume 59, Pages 195-225.
    https://www.sciencedirect.com/science/article/pii/B9780444641793000062
  9. Corzo L, Fernández-Novoa L, Carrera I, Martínez O, Rodríguez S, Alejo R and Cacabelos R. 2020. Nutrition, Health, and Disease: Role of Selected Marine and Vegetal Nutraceuticals. Nutrients, 12(3):747.
    https://www.mdpi.com/2072-6643/12/3/747

HepatoSar

Hepatoprotector. Favorece la función digestiva e intestinal. Previene la formación de cálculos biliares.

Ficha técnica
Data Sheet
  1. Lombardi VRM and Cacabelos R. 1999. E-SAR-94010®: a marine fish extract obtained by advanced biotechnological methods. Drugs of the Future, 24(2): 167-176.
    https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=527660&p_IsPs=N
  2. Lombardi VRM, Cagiao A, Fernández-Novoa L, Álvarez XA, Corzo MD, Zas R, Sampedro C and Cacabelos R. 2001. Short term food supplementation effects of a fish derived extract on the immunological status of pregnant rats and their sucking pups. Nutrition Research, 21: 1425-1434.
    https://www.sciencedirect.com/science/article/pii/S027153170100361X
  3. Cacabelos R, Vallejo AI, Lombardi VRM, Fernández-Novoa L and Pichel V. 2004. E-SAR-94010®: a pleiotropic lipoprotein compound with powerful anti-atheromatous and lipid lowering effects. CNS Drug Reviews, vol. 10 (2).
    https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3458.2004.tb00021.x
  4. Cacabelos R. 2005. Role of Nutrition in the Prevention of Alzheimer´s Disease. Aging Health, 1(3): 359-362.
    https://www.futuremedicine.com/doi/abs/10.2217/1745509X.1.3.359
  5. Cacabelos R. 2005. Pharmacogenomics, nutrigenomics, and therapeutic optimization in Alzheimer’s disease. Future Medicine. Aging Health, 1(2):303-348.
    https://www.futuremedicine.com/doi/10.2217/1745509X.1.2.303
  6. Cacabelos R. 2008. Application of nutrigenomics to Alzheimer’s disease. Agro Food Industry Hi-Tech. 19.
  7. Cacabelos, R. 2008. Pharmacogenomics in Alzheimer’s disease. Meth Mol Biol, 448:213-357.
    10.1007/978-1-59745-205-2_10
  8. Cacabelos R, Fernández-Novoa L, Martínez-Bouza R, McKay A, Carril JC, Lombardi V, et al. 2010. Future trends in the pharmacogenomics of brain disorders and dementia: Influence of APOE and CYP2D6 variants. Pharmaceuticals 3:3040-3100.
    https://doi.org/10.3390/ph3103040
  9. Cacabelos R. 2016. Novel Biotechnological Products from Natural Sources: Nutri/Pharmacogenomic Component. J Nutr Food Sci, 6:6.
    https://www.longdom.org/open-access/novel-biotechnological-products-from-natural-sources-nutri-pharmacogenomic-component-2155-9600-1000e135.pdf
  10. Cacabelos R, Carril JC, Cacabelos P, Teijido O, Goldgaber D. 2016. Pharmacogenomics of Alzheimer’s Disease: Genetic Determinants of Phenotypic Variation and Therapeutic Outcome. J Genomic Med Pharmacogenomics, 1(2): 151-209.
  11. Cacabelos R. 2017. ProteoLipins and LipoFishins: Novel nutraceuticals and their effects. Open Access Government. Health & Social Care News, January 20.
  12. Cacabelos R, Carril JC, Teijido O. 2017. Chapter 5. Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development. Anti-aging Drugs: From Basic Research to Clinical Practice, 75-141.
    https://pubs.rsc.org/en/content/chapter/bk9781782624356-00075/978-1-78262-435-6
  13. Cacabelos R, Meyyazhagan A, Carril JC, Cacabelos R, Teijido O. 2018. Pharmacogenetics of vascular risk factors in Alzheimer’s Disease. J Pers Med, 8(3).
    https://doi.org/10.3390/jpm8010003
  14. Cacabelos R, Lombardi VRM, Fernández-Novoa l, Carrera I, Cacabelos P, Corzo L, Carril JC, Teijido O. 2018. Chapter 6 – Basic and Clinical Studies with Marine LipoFishins and Vegetal Favalins in Neurodegeneration and Age-Related Disorders. Volume 59, Pages 195-225.
    https://www.sciencedirect.com/science/article/pii/B9780444641793000062
  15. Corzo L, Fernández-Novoa L, Carrera I, Martínez O, Rodríguez S, Alejo R and Cacabelos R. 2020. Nutrition, Health, and Disease: Role of Selected Marine and Vegetal Nutraceuticals. Nutrients, 12(3):747.
    https://www.mdpi.com/2072-6643/12/3/747
  16. Salem MB, Affes H, Ksouda K, Dhouibi R, Sahnoun Z, Hammami S, Zeghal KM. 2015. Pharmacological Studies of Artichoke Leaf Extract and Their Health Benefits. Plant Foods Hum Nutr, 70(4):441-53.
    https://link.springer.com/article/10.1007/s11130-015-0503-8
  17. Salekzamani S, Ebrahimi‐Mameghani M, and Rezazadeh K. 2019. The antioxidant activity of artichoke (Cynara scolymus): A systematic review and meta‐analysis of animal studies. Phytother Res, 33(1):55-71.
    https://onlinelibrary.wiley.com/doi/abs/10.1002/ptr.6213

LipoEsar

Hipolipemiante y antiaterosclerótico. Disminuye el colesterol y los triglicéridos. Mejora la salud cardiovascular.

Ficha técnica
Data Sheet
  1. Lombardi VRM and Cacabelos R. 1999. E-SAR-94010®: a marine fish extract obtained by advanced biotechnological methods. Drugs of the Future, 24(2): 167-176.
    https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=527660&p_IsPs=N
  2. Lombardi VRM, Cagiao A, Fernández-Novoa L, Álvarez XA, Corzo MD, Zas R, Sampedro C and Cacabelos R. 2001. Short term food supplementation effects of a fish derived extract on the immunological status of pregnant rats and their sucking pups. Nutrition Research, 21: 1425-1434.
    https://www.sciencedirect.com/science/article/pii/S027153170100361X
  3. Cacabelos R, Vallejo AI, Lombardi VRM, Fernández-Novoa L and Pichel V. 2004. E-SAR-94010®: a pleiotropic lipoprotein compound with powerful anti-atheromatous and lipid lowering effects. CNS Drug Reviews, vol. 10 (2).
    https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3458.2004.tb00021.x
  4. Cacabelos R. 2005. Role of Nutrition in the Prevention of Alzheimer´s Disease. Aging Health, 1(3): 359-362.
    https://www.futuremedicine.com/doi/abs/10.2217/1745509X.1.3.359
  5. Cacabelos R. 2005. Pharmacogenomics, nutrigenomics, and therapeutic optimization in Alzheimer’s disease. Future Medicine. Aging Health, 1(2):303-348.
    https://www.futuremedicine.com/doi/10.2217/1745509X.1.2.303
  6. Cacabelos R. 2008. Application of nutrigenomics to Alzheimer’s disease. Agro Food Industry Hi-Tech. 19.
  7. Cacabelos, R. 2008. Pharmacogenomics in Alzheimer’s disease. Meth Mol Biol, 448:213-357.
    10.1007/978-1-59745-205-2_10
  8. Cacabelos R, Fernández-Novoa L, Martínez-Bouza R, McKay A, Carril JC, Lombardi V, et al. 2010. Future trends in the pharmacogenomics of brain disorders and dementia: Influence of APOE and CYP2D6 variants. Pharmaceuticals 3:3040-3100.
    https://doi.org/10.3390/ph3103040
  9. Cacabelos R. 2016. Novel Biotechnological Products from Natural Sources: Nutri/Pharmacogenomic Component. J Nutr Food Sci, 6:6.
    https://www.longdom.org/open-access/novel-biotechnological-products-from-natural-sources-nutri-pharmacogenomic-component-2155-9600-1000e135.pdf
  10. Cacabelos R, Carril JC, Cacabelos P, Teijido O, Goldgaber D. 2016. Pharmacogenomics of Alzheimer’s Disease: Genetic Determinants of Phenotypic Variation and Therapeutic Outcome. J Genomic Med Pharmacogenomics, 1(2): 151-209.
  11. Cacabelos R. 2017. ProteoLipins and LipoFishins: Novel nutraceuticals and their effects. Open Access Government. Health & Social Care News, January 20.
  12. Cacabelos R, Carril JC, Teijido O. 2017. Chapter 5. Pharmacogenomics and Epigenomics of Age-Related Neurodegenerative Disorders: Strategies for Drug Development. Anti-aging Drugs: From Basic Research to Clinical Practice, 75-141.
    https://pubs.rsc.org/en/content/chapter/bk9781782624356-00075/978-1-78262-435-6
  13. Cacabelos R, Meyyazhagan A, Carril JC, Cacabelos R, Teijido O. 2018. Pharmacogenetics of vascular risk factors in Alzheimer’s Disease. J Pers Med 2018; 8(3).
    https://doi.org/10.3390/jpm8010003
  14. Cacabelos R, Lombardi VRM, Fernández-Novoa l, Carrera I, Cacabelos P, Corzo L, Carril JC, Teijido O. 2018. Chapter 6 – Basic and Clinical Studies with Marine LipoFishins and Vegetal Favalins in Neurodegeneration and Age-Related Disorders. Volume 59, Pages 195-225.
    https://www.sciencedirect.com/science/article/pii/B9780444641793000062
  15. Corzo L, Fernández-Novoa L, Carrera I, Martínez O, Rodríguez S, Alejo R and Cacabelos R. 2020. Nutrition, Health, and Disease: Role of Selected Marine and Vegetal Nutraceuticals. Nutrients, 12(3):747.
    https://www.mdpi.com/2072-6643/12/3/747

MakaliSex

Mejora la salud sexual en hombres y en mujeres. Indicado para problemas de infertilidad en el hombre. Energizante.

Ficha técnica
Data Sheet
  1. Gonzales GF. 2012. Ethnobiology and Ethnopharmacology of Lepidium meyenii (Maca), a Plant from the Peruvian Highlands. Evid Based Complement Alternat Med, 2012:193496.
    https://www.hindawi.com/journals/ecam/2012/193496/
  2. Zenico T, Cicero AF, Valmorri L, Mercuriali M, Bercovich E. 2009. Subjective effects of Lepidium meyenii (Maca) extract on well-being and sexual performances in patients with mild erectile dysfunction: a randomised, double-blind clinical trial. Andrologia, 41(2):95-9.
    https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1439-0272.2008.00892.x
  3. Lee MS, Shin BC, Yang EJ, Lim HJ, Ernst E. 2011. Maca (Lepidium meyenii) for treatment of menopausal symptoms: A systematic review. Maturitas, 70(3):227-33.
    https://www.maturitas.org/article/S0378-5122(11)00262-3/fulltext
  4. Qazi IH, Angel C, Yang H, Zoidis E, Pan B, Wu Z, Ming Z, Zeng CJ, Meng Q, Han H, Zhou G. 2019. Role of Selenium and Selenoproteins in Male Reproductive Function: A Review of Past and Present Evidence. Antioxidants (Basel), 2;8(8):268.
    https://www.mdpi.com/2076-3921/8/8/268
  5. Prasad AS, Mantzoros CS, Beck FW, Hess JW, Brewer GJ. 1996. Zinc status and serum testosterone levels of healthy adults. Nutrition, 12(5):344-348.
    https://www.sciencedirect.com/science/article/abs/pii/S089990079680058X?via%3Dihub

MineraXin

Para la salud ósea y articular. Útil en la prevención de la osteoporosis. Aumenta la vitamina D. Mejora la sintomatología asociada a la menopausia y perimenopausia.

Ficha técnica
Data Sheet
  1. Corzo L, Rodríguez S, Lombardi V, Alejo R, Cacabelos R. 2013. Propiedades biológicas de MineraXin. Gen-T 9: 31-39.
  2. Cacabelos R. 2016. Novel Biotechnological Products from Natural Sources: Nutri/Pharmacogenomic Component. J Nutr Food Sci, 6:6.
    https://www.longdom.org/open-access/novel-biotechnological-products-from-natural-sources-nutri-pharmacogenomic-component-2155-9600-1000e135.pdf
  3. Cacabelos R. 2017. ProteoLipins and LipoFishins: Novel nutraceuticals and their effects. Open Access Government. Health & Social Care News, January 20.
    https://www.openaccessgovernment.org/proteolipins-lipofishins-novel-nutraceuticals-effects/31137/
  4. Corzo L, Rodriguez S, Alejo R, Fernandez-Novoa L, Aliev G, Cacabelos R. 2017. E-MHK-0103 (Mineraxin™): A Novel Nutraceutical with Biological Properties in Menopausal Conditions. Curr Drug Metab, 18(1):39-49.
    https://www.eurekaselect.com/146323/article
  5. Cacabelos R, Lombardi VRM, Fernández-Novoa l, Carrera I, Cacabelos P, Corzo L, Carril JC, Teijido O. 2018. Chapter 6 – Basic and Clinical Studies with Marine LipoFishins and Vegetal Favalins in Neurodegeneration and Age-Related Disorders. Volume 59, Pages 195-225.
    https://www.sciencedirect.com/science/article/pii/B9780444641793000062
  6. Corzo L, Fernández-Novoa L, Carrera I, Martínez O, Rodríguez S, Alejo R and Cacabelos R. 2020. Nutrition, Health, and Disease: Role of Selected Marine and Vegetal Nutraceuticals. Nutrients, 12(3):747.
    https://www.mdpi.com/2072-6643/12/3/747
  7. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, Bjelakovic M, Gluud C. 2011. Vitamin D supplementation for prevention of mortality in adults. Cochrane Database of Systematic Reviews 2011, Issue 7. Art. No.: CD007470.
    https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007470.pub2/full
  8. Grienke U, Silke J, Tasdemir D. 2014. Bioactive compounds from marine mussels and their effects on human health. Food Chem, 142:48-60.
    https://www.sciencedirect.com/science/article/abs/pii/S0308814613009539?via%3Dihub

NeoBrainine

Nutriente cerebral. Trastornos neurológicos. Problemas de memoria. Deterioro cognitivo. Patología cerebrovascular. Demencias.

Ficha técnica
Data Sheet
  1. Cacabelos R, Álvarez XA, Franco A, Fernández-Novoa L, Caamaño J, Valle-Inclán F. 1992. Therapeutic effects of CDP-choline in Alzheimer’s disease and multi-infarct dementia: psychometric assessment and immune function. Ann Psychiat, 3: 233-245.
  2. Cacabelos R, Alvarez XA, Franco-Maside A, Fernández-Novoa L, Caamaño J. 1993. Effect of CDP-choline on cognition and immune function in Alzheimer’s disease and multi-infarct dementia. Ann N Y Acad Sci. 24, 695:321-3.
    10.1111/j.1749-6632.1993.tb23076.x  
  3. Caamaño J, Gómez MJ, Franco A, Cacabelos R. 1994. Effects of CDP-choline on cognition and cerebral hemodynamics in patients with Alzheimer’s disease. Methods Find Exp Clin Pharmacol, 16(3): 211-8.
    PMID: 7913981
  4. Fernández-Novoa L, Alvarez XA, Franco-Maside A, Caamaño J, Cacabelos R. 1994. CDP-choline-induced blood histamine changes in Alzheimer’s disease. Methods Find Exp Clin Pharmacol, 16(4): 279-84.
    PMID: 8051988
  5. Franco-Maside A, Caamaño J, Gómez MJ, Cacabelos R. 1994. Brain mapping activity and mental performance after chronic treatment with CDP-choline in Alzheimer’s disease. Methods Find Exp Clin Pharmacol, 16(8): 597-607. Clinical Trial
    PMID: 7760585
  6. Cacabelos R, Caamaño J, Gómez MJ, Fernández-Novoa L, Franco-Maside A, Vinagre D, Novo B, Zas R, Álvarez XA. 1995. Treatment of Alzheimer’s disease with CDP-choline: Effects on mental performance, brain electrical activity, cerebrovascular parameters, and cytokine production. Ann Psychiat, 5: 295-315.
  7. Alvarez XA, Laredo M, Corzo D, Fernández-Novoa L, Mouzo R, Perea JE, Daniele D, Cacabelos R. 1997. Citicoline improves memory performance in elderly subjects. Methods Find Exp Clin Pharmacol, 19(3): 201-10.
    PMID: 9203170 Clinical Trial.
  8. Alvarez XA, Mouzo R, Pichel V, Pérez P, Laredo M, Fernández-Novoa L, Corzo L, Zas R, Alcaraz M, Secades JJ, Lozano R, Cacabelos R. 1999. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer’s disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion. Methods Find Exp Clin Pharmacol, 21(9):633-44. Clinical Trial.
    PMID: 10669911
  9. Álvarez XA, Sampedro C, Cacabelos R. 1999. Antiapoptotic effects of CDP-choline in a combined (Ab4/hypoperfusion) animal model of hippocampal neurodegeneration. Ann Psychiatry, 7:147-156.
0